What this is
- How it works
- JAK1/JAK2 inhibitor
- How it’s given
- “Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg”In the company’s words, NCT07617597 on ClinicalTrials.gov
- Tested for
- Alopecia Areata (3 trials)
- Main trialPhase 3
- “This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.”In the company’s words, NCT07617597 on ClinicalTrials.gov
- Other names
- CTP-543 · Leqselvi
Other drugs for Alopecia Areata
- RitlecitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- ALD-102Aldena Therapeutics · Phase 1/2
- SYHX1901CSPC · Phase 2
- LAD603Almirall, S.A. · Phase 2
- LY4005130Eli Lilly · Phase 2
Coming up3
- May 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Feb 2028Phase 3 trial completes · ClinicalTrials.gov
- May 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2028 | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata | |
| Phase 3Recruiting | May 2028 | Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata | |
| Phase 2/3Active, not recruiting | May 2027 | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | |
| Phase 3Completed | 19 Apr 2022 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) | |
| Phase 3Completed | 8 Jun 2022 | Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) | |
| Phase 3Completed | 18 Jul 2024 | European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | |
| Phase 2Completed | 8 Jul 2019 | Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata | |
| Phase 2Completed | 21 Nov 2019 | Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata | |
| Phase 2Completed | 10 Apr 2020 | Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata | |
| Phase 2Completed | 16 May 2023 | A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata | |
| Phase 1Completed | 27 Mar 2021 | Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects | |
| Phase 1Completed | 24 Jun 2021 | Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects | |
| Phase 1Completed | 28 Jan 2022 | A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers | |
| Phase 1Completed | 26 Jun 2022 | Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers | |
| Phase 1Completed | 30 Jun 2022 | Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects | |
| Phase 1Completed | 6 Aug 2022 | Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects | |
| Phase 1Completed | 15 Sep 2022 | Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543 | |
| Phase 1Completed | 20 Oct 2022 | Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026